340B Pricing, Penalty Alternatives Will Be Reassessed; Final Rule Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma pushback pays off as HRSA requests additional public comment on key issues, including 340B ceiling prices and manufacturer civil monetary penalties.